Archive for July, 2010

Incredibly, FDA urged Florida not to bar foster kids from drug trials, arguing “benefits” can outweigh risks.

Monday, July 26th, 2010

HeraldTribune.com
By Tom Lyons
July 25, 2010

Apparently the U.S. Food and Drug Administration had at least heard about the suicide of Gabriel Myers.

The real reason: He was 7 years old.

Whatever else might have helped lead such a young child toward ending his life, one detail was impossible to ignore: The boy was being treated with three different psychotropic medications.

Medications of that sort make some people more depressed or even suicidal, and their effects when combined are harder to predict, especially in children.

So DCF did a quick check on how many foster children were being given such drugs. Troubling facts emerged.

Not only was the percentage high, it was not really known. And, in more than a third of known cases, required approval permission documents were missing.

DCF Secretary George Sheldon quickly acknowledged the problem and started a study group to learn more and give advice. And a year later, the picture is at least more clear. Very few files lack required documentation now. And when I asked for the most current numbers, they were available, and somewhat lower. In the Sarasota-Manatee-DeSoto county region, 11 percent of foster children are given psychotropic meds. Statewide, it is 13 percent.

Some critics insist too many foster parents, lacking the skill or patience to work with troubled children who arrive as strangers, are still too quick to see medication as the way to curb problem behavior or just keep foster children quiet, no matter the side effects.

But whatever the truth of that, the study group recommended some good changes, and one made sense immediately, I thought: Ban the use of foster kids in drug trials.

Drugs helpful to some adults can react differently in children, who may suffer more extreme and unintended side effects. And so, clinical trials on children are needed, but it it is a scary field of study. The most alert and caring parents are key for monitoring the children during such trials, I would think.

So I was surprised at the FDA’s response when Sheldon wrote to ask how many Florida foster children were involved in drug studies as they bounce from foster family to foster family.

Jill Hartzler, an associate FDA commissioner, responded that the FDA — which oversees the studies to make sure children’s involvement is approved and understood by parents or guardians — didn’t have an exact number. Or even an estimate. The FDA, in fact, doesn’t have the slightest idea how many Florida foster kids are or have been involved in its drug studies.

But that wasn’t the weirdest part. Hartzler and the FDA also urged that Florida not bar foster kids from drug trials, arguing that benefits can outweigh risks.

I’m happy to say Sheldon is not taking that advice. But as he explains his reasoning more tactfully than does Richard Wexler of the National Coalition for Child Protection Reform, I’ll quote Wexler, who says the FDA’s position is absurd.

Myers’ death by hanging happened in a Florida foster home last year, but that wasn’t the main reason it triggered a major reaction at Florida’s Department of Children and Families.

Read entire article here: http://www.heraldtribune.com/article/20100725/COLUMNIST/7251032/2055/NEWS?p=1&tc=pg

« Return to news items


Share

Psychiatric drug use skyrockets in U.S. military

Monday, July 26th, 2010

Natural News
By David Gutierrez
July 26, 2010

Use of prescription psychotropics has skyrocketed among U.S. military personnel in recent years, according to an investigation by Military Times.

At least 17 percent of active-duty military personnel are currently taking an antidepressant, including as many as 6 percent of all deployed troops. In contrast, the rate of antidepressant use in the wider U.S. public is only 10 percent.

Overall, one in six military service members takes at least one type of psychiatric drug. The numbers are probably higher than estimated, since troops are also known to share and trade prescription drugs with each other, even while in combat zones.

Data obtained from the Defense Logistics Agency show that overall use of psychiatric drugs increased by 76 percent between 2001 and 2009. More specifically, use of anti-seizure drugs increased 70 percent, use of sedatives and anxiety drugs increased 170 percent, and antipsychotic use increased 200 percent.

Spending on anticonvulsants increased from $16 million to $35 million per year, spending on anxiety drugs and sedatives increased from $6 million to $17 million, and spending on antipsychotics increased from $4 million to $16 million.

Although antidepressants are among the drugs most commonly taken by military personnel, their use increased only 40 percent between 2001 and 2009. Spending actually dropped by 16 percent, likely reflecting the new availability of less-expensive generic drugs.

According to a 2009 study by the Veterans Affairs Administration, approximately 60 percent of psychiatric drug use by military personnel is for “off-label” uses not approved by the FDA. Thus, antipsychotic drugs intended for the treatment of schizophrenia are now being widely prescribed for post-traumatic stress disorder symptoms such as anger, headaches, nervousness and nightmares.

“Patients may be exposed to drugs that have problematic side effects without deriving any benefit,” said Robert Rosenheck of Yale University. “We just don’t know. There haven’t been very many studies.”

Further compounding concern over side effects, many troops regularly mix two or more drugs together into untested cocktails. The effects of multiple drugs acting in unison have rarely been tested. When both drugs act on the same organ — in this case, the brain — the chance of unforeseen interactions is even greater.

“In the case of poly-drug use — the ‘cocktail’ — where you are combining an antidepressant, an anticonvulsant, an antipsychotic, and maybe a stimulant to keep this guy awake — that has never been tested,” Breggin said.

Among the side effects that some health professionals worry about are impaired motor skills, reduced reaction time, increased suicide risk, irritability, aggressiveness and hostility.

“Imagine causing that in men and women who are heavily armed and under a great deal of stress,” psychiatrist Peter Breggin said.

Read entire article:  http://www.naturalnews.com/029285_psychiatric_drugs_military.html

« Return to news items


Share

Leading “brain imaging” center (Pharma funded) studying “biology of mental disorders” gets raided by Feds & shut down

Friday, July 23rd, 2010

(For more information on recently debunked  brain imaging studies on “schizophrenia” see link at bottom of this post)

The New York Times
By Benedict Carey
July 16, 2010

Columbia University has quietly suspended research at a nationally prominent brain-imaging center and reassigned its top managers after federal investigators found that it had routinely injected mental patients with drugs that contained potentially dangerous impurities.

The investigations found that the center — regarded by experts as the nation’s leader in the use of positron emission tomography, or PET, for psychiatric research — repeatedly violated Food and Drug Administration regulations over a four-year period.

“Failure to promptly correct these violations may result in legal action without further notice,” the agency wrote to Columbia in December 2008, citing lax internal quality control and sloppy procedures for formulating drug injections.

F.D.A. investigators returned in January 2010 and found that many of the center’s lab’s practices had not changed, and cited a long list of specific violations, including one instance in which the staff hid impurities from auditors by falsifying documents.

“They raided the place like it was a crime scene, seizing hard drives,” said one former lab worker, who requested anonymity because he feared reprisals from the university.

In a statement, the university said on Friday that it had conducted its own investigation of the lab at the request of the F.D.A. had and reported to the agency on July 6 that it found no evidence of harm to patients. The F.D.A. did not publicize its investigations; The New York Times learned of them from doctors who were familiar with the lab’s problems.

The office under fire, the Kreitchman PET Center, on West 168th Street in Manhattan, has attracted millions of dollars in research funds from the federal government and pharmaceutical companies to study drug actions and the biology of brain disorders, among other things.

Many of its studies focus on patients with disorders like schizophrenia and severe depression, who are especially vulnerable to poorly prepared imaging drugs because the compounds can act on brain receptors involved in their illness.

“We acknowledge serious shortcomings of quality control in the manufacturing process and record-keeping at this lab,” said David I. Hirsh, Columbia’s executive vice president for research. “That is why we are fundamentally reorganizing the lab’s management and operations in response to what the F.D.A. told us.”

To perform a PET scan, doctors must first inject patients with a radiotracer, a drug engineered to accumulate in the area of the body being studied and to emit low-level radiation detectable by a scanner.

The compounds are considered very safe. But because they degrade quickly, many laboratories produce them themselves, under protocols agreed upon with the F.D.A.

The agency regulates the allowable radiation levels and the purity of the drugs. If a drug contains too many impurities — unknown chemicals that may or may not be related to the tracer itself — then its effects in the body are unpredictable.

“There could be a patient safety issue, for one,” said Dr. Barry Siegel, chairman of the radioactive drug research committee at Washington University in St. Louis. “And there could be a scientific validity issue. If you’re exposing people to radiation and getting garbage data, then that becomes an ethical problem.”

Read entire article:  http://www.nytimes.com/2010/07/17/health/17columbia.html

For other recent expose’s on psychiatric brain imaging – see this article:

Anti-Psychotic Drugs are Likely to Cause Brain Damage, According to a New Study—

“The results challenge the widely-held view that schizophrenia itself causes brain structural changes, such as less brain grey matter, bigger ventricles and larger cerebrospinal fluid (CSF) spaces, claim researchers. The results are published in an edition earlier this year of the Psychological Medicine Journal.”

http://psychminded.co.uk/news/news2010/july10/Anti-psychotics-likely-to-cause-brain-damage001.html

« Return to news items


Share

Drug maker to settle 200 lawsuits for failing to warn patients of diabetes risks caused by its antipsychotic drug

Friday, July 23rd, 2010

AboutLawsuits.com
July 23, 2010

AstraZeneca has agreed to settle Seroquel lawsuits filed by about 200 people who claim that the drug maker failed to adequately warn about the risk of diabetes and other side effects of their antipsychotic drug. The Seroquel settlements are reportedly the first payments AstraZeneca has made out of an estimated 26,000 claims that have been presented against the company.

Bloomberg News reports that AstraZeneca has agreed to pay $2 million as a settlement for the Seroquel lawsuits, which comes out to an average of about $10,000 per claim. It is not clear what injuries were involved in these claims, or what the circumstances are for the cases. All of the settled lawsuits involved plaintiffs represented by one attorney, and Bloomberg News reports that the agreement came as a result of court-ordered mediation.

Although AstraZeneca has previously indicated that they would fight all Seroquel cases at trial, company officials now indicate that they will continue to negotiate with plaintiffs’ attorneys.

Seroquel (quetiapine fumarate) is an atypical-antipsychotic that is a top selling drug for AstraZeneca, generating nearly $5 billion a year in sales. Originally approved by the FDA in 1997 for the treatment of schizophrenia, it has been frequently prescribed off-label for uses that were not approved as safe and effective at the time, such as anxiety, obsessive dementia, compulsive disorders and autism.

In July 2006, all Seroquel lawsuits filed in federal courts throughout the United States were consolidated for pretrial litigation before U.S. District Judge Anne Conway in the Middle District of Florida as part of a multidistrict litigation (MDL). In May of this year, Judge Conway determined that the majority of the work in the Seroquel litigation was complete, and began remanding cases back to the original jurisdiction where they were filed for trial.

Read entire article:  http://www.aboutlawsuits.com/settlement-for-seroquel-lawsuits-reached-in-some-cases-11647/

« Return to news items


Share

The New American—Psychiatry’s Brave New World

Friday, July 23rd, 2010

The New American
By Beverly K. Eakman
July 22, 2010

After some 40 years of psychiatry-based “parenting,” free societies are experiencing behaviors by out-of-control children virtually unknown in the 1950s — first-graders biting and kicking their teachers; adolescents blowing away their classmates; pre-teens cursing, spitting, and vandalizing while adults look on. Advocates for a Nanny State see all this as a wedge to further their controlling agenda. Anyone curious as to where we’re headed need look no further than the United Kingdom’s now-institutionalized ASBO legislation.

In July 1998, the U.K.’s Crime and Disorder Act enacted the “Anti-Social Behaviour Orders” (ASBOs) to tackle disagreeable and disruptive acts. ASBOs are court-ordered restrictions on “unsociable conduct” aimed at youngsters aged 10 or over. Breaching an ASBO is a criminal offense.

Eight years into the legislation, some 12,675 ASBOs had been issued. Nearly 2,000 youngsters, aged 10 to 17, were jailed by 2007 for an average of six months each for breaching ASBOs. Even that was not enough. According to Mail Online, May 27, 2007 (“Revealed: Blair’s secret stalker squad”), the government attempted to widen the definition of “mental disorder” so that the right not to be detained in a psychiatric facility based on cultural, political, or religious beliefs would be forfeited.

By 2007, Britain had gone a long way to becoming the ultimate modern police state. The nation had more than 20 percent of the world’s CCTV cameras incorporating automatic number-plate recognition, facial recognition and “suspicious behavior recognition” software, which analyzes clusters and movements in search of “behavioral oddities.” Some £1 million was allocated for hidden loudspeakers so that camera operators could issue orders, very loudly, to anyone seen littering or committing other “gotcha crimes” (petty rules that are easier to enforce than dangerous acts). A competition was even launched in schools to find “socially conscious” children who might be used for voice-overs to “remind adults to act responsibly on our streets,” according to the U.K.’s Home Office.

“Emotional literacy” classes were introduced in schools to teach children how to manage anger and jealousy and develop empathy and self-motivation. This move mirrors the touchy-feely curricular trends of American classrooms — “conflict resolution,” “survival skills,” “safe sex” and “self-esteem.”

Read entire article:  http://thenewamerican.com/index.php/usnews/health-care/4112-psychiatrys-brave-new-world

« Return to news items


Share

The malicious use of pharmaceuticals: An under-recognized form of child abuse

Thursday, July 22nd, 2010

Physorg.com
July 22, 2010

Child abuse is a serious problem that affects nearly one million children a year in the United States alone. The American Academy of Pediatrics and the US Department of Health and Human Services classify child abuse into four categories including neglect, physical abuse, sexual abuse, and emotional abuse. None of these categories, however, clearly includes the abusive use of drugs on children. A study soon to be published in the Journal of Pediatrics investigates the malicious use of pharmaceuticals and attempts to shed light on this under-recognized problem.

Dr. Shan Yin from the University of Colorado and the Rocky Mountain Poison Drug Center at Denver Health reviewed cases of pharmaceutical abuse reported to the National Poison Data System between 2000 and 2008. Dr. Yin included reports of the malicious use of alcohol, painkillers, cough and cold medicines, sedatives and sleeping pills, and antipsychotic medicines.

Of the more than 1400 cases studied, nearly 14% resulted in moderate to major consequences, including death. Nearly one-half of the abused children were exposed to at least one sedative. An average of 160 cases, including two deaths, was reported each year. Motives and legal findings were unavailable for these particular cases; however, motives for the abusive use of drugs generally are varied, and can include punishment, amusement, or a wish for a break from childcare responsibilities.

This study illustrates the seriousness of the abusive use of drugs administered to children.

Read entire article:  http://www.physorg.com/news198936684.html

« Return to news items


Share

Antidepressants the same as placebo “If antidepressants work, why is the prevalence of depression not decreasing?”

Thursday, July 22nd, 2010

The StarPhoenix
By Mark Lemstra
July 22, 2010

We could save $2 billion a year on health-care costs in Saskatchewan while actually improving health outcomes if we adopt evidence-based protocols.

To do so, we need to go line by line through budgets to find about $40 million of efficiencies in each of about 50 areas.

This is the second article in a five-part series on depression. The first one discussed how there is no medical test to diagnose depression; the interview scales have no known validity or reliability because there is no comparative gold standard; the varying interview scales result in different diagnostic conclusions; and almost every life reaction is considered a symptom for depression — including things such as indecisiveness, inability to concentrate, changes in weight or sleeping pattern.

None of this is very scientific.

From 1952 to 1980, the Diagnostic Statistical Manual of Mental Disorders (DSM) described mental disorders as reactions to environmental events such as the death of a loved one.

To make depression seem more medical, the editors of the DSM published a revision in 1980, dismissing environmental influences as causative events.

A small group of practitioners voted and agreed that depression should no longer be diagnosed if the symptoms were caused by factors such as bereavement, substance use or other medical conditions.

Although this purely medical concept is obviously good for pharmaceutical companies, it ignores the reality that almost all cases of depression are triggered by stressful life events.

So let’s review the medical or biological basis for depression.

Numerous theories have been suggested, including noradrenalin abnormalities, cortisol excess, hippocampal insufficiency and neurotrophic factor.

All have been dismissed. The latest theory is neurotransmitter deficiency with a focus on serotonin, although norepinephrine and dopamine are also included.

The problem with this latest theory is that it, too, cannot be backed up by data. Molecular Psychiatry published a literature review of all papers that studied what happens when you lower neurotransmitter levels. It found that depletion did not result in depression.

In other words, low levels of serotonin, norepinephrine or dopamine do not cause depression.

Read entire article:  http://www.thestarphoenix.com/health/Effect+antidepressants+placebos+similar/3307896/story.html

« Return to news items


Share

Chantix & Violence: What Patients Have In Common

Thursday, July 22nd, 2010

Pharmalot
By Ed Silverman
July 22, 2010

For the past three years, the Chantix smoking cessation pill has caused a stir after being associated with suicidal behavior and vivid dreams (see here and here). Consequently, the government banned the Pfizer drug for pilots and licenses wouldn’t be issued to truck drivers taking the med (see this). The FDA subsequently imposed a risk management program and Pfizer added warnings.

Now, a new study in The Annals of Pharmacotherapy finds Chantix is not only associated with violent and agressive thoughts and acts, but has also identified some of the common characteristics among people using the pill and their subsequent behavior. The drug “does have warnings about psychiatric side effects, but it skims over aggression/violence towards others to focus mainly on suicidal behaviors,” says Thomas Moore, one of the co-authors and a senior scientist at the Institute for Safe Medication Practices, a non-profit that has issued reports previously about Chantix side effects.

“We believe this may be the first scientific report to examine the characteristics of aggression/violence as a psychiatric side effect for any prescription drug. What do these cases look like? A question answered for possibly the first time. We found the details striking and chilling. This is the first time we know of that aggression/violence has been clearly documented as a side effect in a peer reviewed scientific journal. This raises the question of whether (Chantix) is suitable for use in the military, by police and others who are already in stress situations. One key characteristic of these events is uncontrollable rage. Not a good side effect for people paid to carry guns.”

The researchers obtained 78 adverse event reports from the FDA MedWatch database containing medical terms describing possible acts or thoughts of aggression/violence; four more cases came from clinical trials, and three others came from published literature. Ultimately, they used 26 case reports for study and these described 10 events with assault, nine cases of homicidal ideation and seven instances of other thoughts or acts of aggression/violence. They noted that the patient population was predominantly middle-aged women, but “an unlikely age group and sex for assault and acts of violence toward others.”

“In all 26 cases,” they write, “the acts or thoughts of violence appeared to be inexplicable and unprovoked. A woman struck her 17-year-old daughter in the mouth while the daughter was driving a car, with a young granddaughter also present. A 42-year-old man punched a stranger at a bowling alley. The stranger and two friends responded and knocked out the subject’s front teeth. A 24-year-old female started beating her boyfriend in bed because he “looked so peaceful” and she later attempted suicide. A 29-year-old female struck an acquaintance twice in the face, and then started smashing doors in her own home and beating on her truck.”

Read entire article:  http://www.pharmalot.com/2010/07/chantix-and-violence-what-patients-have-in-common/

*The package insert for Chantix shows that it contains a type of chemical compound that is better known as benzodiazepine—benzodiazepines are otherwise known as anti-anxiety drugs.

« Return to news items


Share

Glaxo To Pay $1Billion To Settle Paxil Birth Defect Cases

Wednesday, July 21st, 2010

Pharmalot
By Ed Silverman
July 21, 2010

In an effort to get its arms around massive litigation, GlaxoSmithKline has agreed to settle yet another wad of product-liability lawsuits involving one of its popular meds. The latest deal involves an agreement to pay more than $1 billion to settle some 800 cases alleging its Paxil antidepressant caused birth defects in children borne to women who took the drug, Bloomberg News writes.

The move comes after a Pennsylvania state court jury last October awarded a woman $2.5 million in damages for failing to properly warn docs and pregnant women about the risks of the antidepressant. This case, which was filed by the family of a three-year-old boy who was born with heart defects his mother blamed on the drug. It was the first of 600 such lawsuits and was seen as a test of Glaxo’s vulnerability (background).

Last week, Glaxo disclosed plans to take a $2.4 billion charge in its second quarter to settle product-liability lawsuits over its Avandia diabetes pill, litigation involving the Paxil antidepressant and a US government investigation into its manufacturing site at Cidra, Puerto Rico.

The Paxil deal, which would provide an average payout of more than $1.2 million to families of the affected children, leaves more than 100 similar cases pending. The birth-defect settlements bring to more than $2 billion the amount Glaxo has agreed to pay to resolve a variety of Paxil-related suits, including claims the pill caused suicides or attempted suicides and addiction problems, Bloomberg writes.

Read the entire article here:  http://www.pharmalot.com/2010/07/glaxo-to-pay-1b-to-settle-paxil-birth-defect-cases/

See all international studies/warnings on Paxil: http://www.cchrint.org/psychdrugdangers/drug_warnings.php

See what doctors, pharmacists, health care providers and others have reported to the US FDA on Paxil side effects (such as birth defects): http://www.cchrint.org/psychdrugdangers/medwatch_psych_drug_adverse_reactions.php

« Return to news items


Share

Psychiatric Meds 101—A layman’s guide to drug side effects—by award winning Scientist Shane Ellison

Wednesday, July 21st, 2010

By Shane “The People’s Chemist” Ellison
Author, Over-The-Counter Natural Cures

I may be a perfect candidate for psychiatry.

I ask questions with period marks to shorten conversations. I avoid eye contact with strangers in fear (maybe it’s anxiety) that I might learn too much about them. I secretly think that Metallica would be making better music if they went back to bludgeoning themselves with party drugs and alcohol, instead of “therapy.” I’m trying to master the Law of Un-attraction to shield myself from a “real job,” small homes and junky cars.  And, I’m constantly giving my children advice, only to give it to myself.

Psychiatry, can your drugs help me?

Perhaps these questions are what motivated me to pursue a career as a drug design chemist, winning multiple awards for my work. Nothing gets me more excited than drugs and how they affect the body (except my wife’s abs). I’ve studied their molecular anatomy, risked life and limb to mix and match explosive chemicals in a round bottom flask, and even sold my soul to Big Pharma in exchange for a lab bench and chemical hood.

During this time, I’ve made some surprising discoveries about psychiatric meds, which include antidepressants, antipsychotics, stimulants, and anti-anxiety drugs. Understanding what I’ve learned will protect you from the flood of side effects that are now being discovered at breakneck speeds, courtesy of the myriad of patients being prescribed psychiatric drugs in the name of mental health.

Your Own Personal Hell

Antidepressants strive to increase the levels of a “coping” molecule known as serotonin in the brain. It supposedly helps us find happiness when it’s covered in an avalanche of nastiness. But, it’s never been proven. Still, the drugs attempt to boost serotonin by “selectively” stopping the “reuptake” among brain cells. This is where the whole SSRI acronym came from—“selective serotonin reuptake inhibitor.” It’s a slick name, but a stupid idea. Nothing is selective in the body.

Read the rest of this article here: http://www.cchrint.org/2010/07/20/psychiatric-meds-101-a-surprising-discovery/

« Return to news items


Share